PITTSBURGH – Locally-based Cellomics Inc. has signed a long-termon the new Bridgeside Point building at the Pittsburgh Technology Center. Slated for completion in December 2001, the 153,000 sq. ft., five-story building will be a state-of-the-art biotechnology facility.
The new facility will allow Cellomics to consolidate its Harmar Township, Pa., operations with its manufacturing facility. The company will sublease a portion of space in the building, which is being developed by Ferchill Group. Colliers Penn served as broker to Cellomics.